Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mozavaptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 known ✓ | P30518 | 4/20 | 0.98 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.98 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | OXTR | P30559 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mozavaptan SCHEMBL29872549 | 1.00 | AVPR1A (0.98) | AVPR1AAVPR2AVPR1BABCB11HTR1A | |
| Mozavaptan SCHEMBL29388889 | 0.99 | AVPR1A (1.00) | AVPR1AAVPR2AVPR1BABCB11HTR1A | |
| Mozavaptan SCHEMBL15084884 | 0.99 | AVPR1A (1.00) | AVPR1AAVPR2AVPR1BABCB11HTR1A | |
| Mozavaptan SCHEMBL1649322 | 0.99 | AVPR1A (1.00) | AVPR1AAVPR2AVPR1BABCB11HTR1A | |
| SCHEMBL6971372 | 0.92 | AVPR1A (0.86) | AVPR1AAVPR2AVPR1BABCB11HTR1A | |
| SCHEMBL7345848 | 0.90 | AVPR1A (0.83) | AVPR1AAVPR2AVPR1BABCB11HTR1A | |
| SCHEMBL4139770 | 0.90 | AVPR1A (0.83) | AVPR1AAVPR2AVPR1BABCB11HTR1A | |
| SCHEMBL7352047 | 0.90 | AVPR1A (0.82) | AVPR1AAVPR2AVPR1BABCB11HTR1A | |
| SCHEMBL7343097 | 0.89 | AVPR1A (0.82) | AVPR1AAVPR2AVPR1BABCB11HTR1A | |
| SCHEMBL7344618 | 0.89 | AVPR1A (0.82) | AVPR1AAVPR2AVPR1BABCB11HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2591806-A1 | Medicinal composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-05-15 | — | — | EP | claimed |
| US-7008920-B2 | Medicinal composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-03-07 | — | — | US | claimed |
| US-20050095290-A1 | Medicinal composition | OTSUKA PHARMACEUTICAL CO., LTD. | 2005-05-05 | — | — | US | claimed |
| US-6884768-B2 | Using taurine compound; adjust bioavailability; prevent, suppression damage to intestine mucous membrane | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-26 | — | — | US | claimed |
| US-20040161407-A1 | Medicinal compositions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-19 | — | — | US | claimed |
| EP-1407785-A1 | MEDICINAL COMPOSITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-14 | — | — | EP | claimed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| CN-115487195-B | New application of mozavaptan compound and medicine | 中南大学湘雅医院 | 2023-08-01 | — | — | CN | disclosed |
| CN-115487195-A | New application and medicine of mozavaptan compounds | 中南大学湘雅医院 | 2022-12-20 | — | — | CN | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11110098-B2 | Methods and medicaments for the treatment of renal cell carcinoma | UNIVERSITY OF KANSAS (US) | 2021-09-07 | — | — | US | disclosed |
| EP-1407785-A1 | MEDICINAL COMPOSITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-5985869-A | USEFUL AS VASODILATORS, HYPOTENSIVE AGENTS, WATER DIURETICS, PLATELET AGGLUTINATION INHIBITORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1999-11-16 | — | — | US | disclosed |
| US-5753677-A | Benzoheterocyclic compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5559230-A | VASOPRESSIN ANTAGONISTS, QUINOLINES, BENZAZEPINES, VASODILATION, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| EP-0450097-B1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1996-04-24 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | AVPR2 1018/4885AVPR1A 1282/4885AVPR1B 1419/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | AVPR2 1018/4885AVPR1A 1282/4885AVPR1B 1419/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | AVPR2 3337/4885AVPR1A 3673/4885AVPR1B 3770/4885 |
| US-11110098-B2 | Methods and medicaments for the treatment of renal cell carcinoma | AVPR2, RCC2, VHL | AVPR2 1/4885AVPR1A 7/4885AVPR1B 5/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | AVPR2 1018/4885AVPR1A 1282/4885AVPR1B 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.